Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients

References

• Mammen A. L.. Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Ann. NY Acad. Sci.. 2010; 1184:134–153.
   PubMed Web of Science ®Google Scholar
• Sarkar K., Miller F. W.. Autoantibodies as predictive and diagnostic markers of idiopathic inflammatory myopathies. Autoimmunity. 2004; 37:291–294.
   PubMed Web of Science ®Google Scholar
• Ghirardello A., Zampieri S., Tarricone E., . Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity. 2006; 39:217–221.
   PubMed Web of Science ®Google Scholar
• La Corte R., LoMonaco A., Locaputo A., Dolzani F., Trotta F.. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity. 2006; 39:249–253.
   PubMed Web of Science ®Google Scholar
• Ghirardello A., Zampieri S., Iaccarino L., . Anti-Mi-2 antibodies. Autoimmunity. 2005; 38:79–83.
   PubMed Web of Science ®Google Scholar
• Zampieri S., Ghirardello A., Iaccarino L., . Anti-Jo-1 Antibodies. Autoimmunity. 2005; 38:73–78.
   PubMed Web of Science ®Google Scholar
• Mielnik P., Wiesik-Szewczyk E., Olesinska M., Chwalinska-Sadowska H., Zabek J.. Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies. Autoimmunity. 2006; 39:243–247.
   PubMed Web of Science ®Google Scholar
• Yoshifuji H., Fuji T., Kobayash S., . Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity. 2006; 39:233–241.
   PubMed Web of Science ®Google Scholar
• Hoshino K., Muro Y., Sugiura K., . Anti-MDA5 and anti-TIF1-γ antibodies have clinical significance for patients with dermatomyositis. Rheumatology. 2010; 49:1726–1733.
   PubMed Web of Science ®Google Scholar
• Betteridge Z., Gunawardena H., North J., McHugh N.. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum.. 2007; 56:3132–3137.
   PubMedGoogle Scholar
• Betteridge Z. E., Gunawardena H., Chinoy H., . Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target in UK Caucasian adult-onset myositis. Ann. Rheum. Dis.. 2009; 68:1621–1625.
   PubMed Web of Science ®Google Scholar
• Ghirardello A., Zampieri S., Tarricone E., . Cutting edge issues in polymyositis. Clinic Rev. Allerg. Immunol.. 2011; 41:179–189.
   PubMedGoogle Scholar
• Muro Y., Ishikawa A., Sugiura K., Akiyama M.. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies. Rheumatology. 2012; 51:1508–1513.
   PubMed Web of Science ®Google Scholar
• Bohan A., Peter J. B.. Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med.. 1975; 292:344–347.
   PubMed Web of Science ®Google Scholar
• Bohan A., Peter J. B.. Polymyositis and dermatomyositis (second of two parts). N. Engl. J. Med.. 1975; 292:403–407.
   PubMed Web of Science ®Google Scholar
• Sontheimer R. D.. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?. J. Am. Acad. Dermatol.. 2002; 46:626–636.
   PubMed Web of Science ®Google Scholar
• Bohan A., Peter J. B., Bowman R. L., Pearson C. M.. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine. 1977; 56:255–286.
   PubMed Web of Science ®Google Scholar
• Chinoy H., Fertig N., Oddis C. V., Ollier W. E., Cooper R. G.. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann. Rheum. Dis.. 2007; 66:1345–1349.
   PubMed Web of Science ®Google Scholar
• Ishikawa A., Muro Y., Sugiura K., Akiyama M.. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology (Oxford). 2012; 51:1181–1187.
   PubMed Web of Science ®Google Scholar
• Watanabe A., Kodera M., Sugiura K., . Anti-DFS70 antibodies in 597 healthy workers. Arthritis Rheum.. 2004; 50:892–900.
   PubMed Web of Science ®Google Scholar
• Watanabe K., Muro Y., Sugiura K., Tomita Y.. IgE and IgG4 autoantibodies against DFS70/LEDGF in atopic dermatitis. Autoimmunity. 2011; 44:511–519.
   PubMed Web of Science ®Google Scholar
• Muro Y., Sugiura K., Hoshino K., Akiyama M.. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford). 2012; 51:800–804.
   PubMed Web of Science ®Google Scholar
• Minai O. A.. Pulmonary hypertension in polymyositis-dermatomyositis: clinical and hemodynamic characteristics and response to vasoactive therapy. Lupus. 2009; 18:1006–1010.
   PubMedGoogle Scholar
• Betteridge Z. E., Gunawardena H., McHugh N. J.. Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res. Ther.. 2011; 13:R209.
   PubMed Web of Science ®Google Scholar
• Rosendorff A., Sakakibara S., Lu S., . NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression. Proc. Natl. Acad. Sci. USA. 2006; 103:5308–5313.
   PubMedGoogle Scholar
• Stielow B., Sapetschnig A., Krüger I., . Identification of SUMO-dependent chromatin-associated transcriptional repression components by a genome-wide RNAi screen. Mol. Cell. 2008; 29:742–754.
   PubMed Web of Science ®Google Scholar
• Agricola E., Randall R. A., Gaarenstroom T., Dupont S., Hill C. S.. Recruitment of TIF1γ to chromatin via its PHD finger-bromodomain activates its ubiquitin ligase and transcriptional repressor activities. Mol. Cell. 2011; 43:85–96.
   PubMed Web of Science ®Google Scholar